Position in TRVI
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$393,626
+$141,736 QoQ
Shares Held
21,106
-0.0% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#145
of 216 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PROFUND ADVISORS LLC holds $162,985,629 across 169 Biotechnology names. TRVI ranks #110 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
23,398 | $11,622,488 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,444 | $6,512,251 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
13,814 | $4,158,428 | |
| 4 | MRNA |
Moderna, Inc.
|
33,142 | $2,320,934 | |
| 5 | APGE |
Apogee Therapeutics, Inc.
|
17,163 | $2,278,044 | |
| 6 | CYTK |
Cytokinetics Inc
|
25,572 | $2,178,478 | |
| 7 | KRYS |
Krystal Biotech, Inc.
|
5,770 | $2,144,535 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
18,455 | $2,116,234 |
All Filings in TRVI
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $393,626 | 21,106 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $251,890 | 21,114 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $242,612 | 19,378 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $183,942 | 20,103 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $98,782 | 18,059 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||